Alnylam (ALNY) Stock Stalls As TTR Sales Top $1b And Guidance Tightens

Alnylam Pharmaceuticals just put up blockbuster TTR drug revenue while the stock barely moved. Shares closed at US$205.52, essentially flat on the day, even as second quarter net product sales reached about US$1.2b and global transthyretin amyloidosis revenue crossed US$1b in a single quarter for the first time.

That muted one day reaction sits awkwardly against a company that is now solidly profitable on a trailing twelve month basis and posting several hundred million dollars of non GAAP operating income. The market is treating this as business as usual. The earnings print appears closer to an inflection point.

Impressed by Alnylam Pharmaceuticals turning in over US$1.2b in quarterly product sales while the stock stayed flat, but want more ideas that pair strong fundamentals with market skepticism? Take a look at the 20 high quality undiscovered gems

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs Q2 2025: US$1,290.9m vs. US$773.7m (very large increase from prior year quarter)
• Net Income, Q2 2026 vs Q2 2025: Profit of US$164.5m vs. loss of US$66.3m (moved from loss to profit year on year)
• Basic EPS, Q2 2026 vs Q2 2025: US$1.23 vs. loss of US$0.51 per share (turned from loss per share to positive earnings per share)
• Global TTR Net Revenues, Q2 2026 vs Q2 2025: About US$1.03b vs. about US$0.55b (company reported 89% year on year growth)

Prefer clean visual charts instead of another dense wall of earnings tables and footnotes? See how Alnylam Pharmaceuticals compares in a full valuation snapshot, presented in one clear view through the company report for Alnylam Pharmaceuticals.

Evaluating Whether Alnylam’s Bull Story Is Being Earned

The bullish pitch on Alnylam Pharmaceuticals is that an RNAi TTR franchise, led by AMVUTTRA, can build first line dominance, scale efficiently and fund a broader pipeline. Q2 results go a long way toward hitting those operational milestones. Global TTR revenue cleared about US$1.03b in the quarter and now represents the bulk of the roughly US$1.2b in net product sales. This supports the idea of franchise centrality rather than just a supporting asset.

Execution metrics also line up with the narrative of rapid, quality uptake. AMVUTTRA reached over US$1b in quarterly sales roughly 15 months into the ATTR cardiomyopathy launch, with about 80% of new patient starts now first line, adherence above 90% and more than 1,700 new prescribers added. Non GAAP operating income of US$318m, alongside a product gross margin of 75% despite higher royalties, points to early operating leverage that the bull case has been banking on.

Compare Alnylam Pharmaceuticals’ rapid TTR uptake, high adherence and early operating leverage with what the street is pricing in. See the consensus price target analysis for Alnylam Pharmaceuticals

Alnylam Bear Concerns Shift From Demand To Durable Growth Quality

The core bearish worry on Alnylam Pharmaceuticals is that a TTR heavy model hits saturation quickly while rising R&D and SG&A keep pressure on margins. Q2 gives bears a mixed scorecard. On the one hand, TTR revenue of about US$1.03b and non GAAP operating income of US$318m point to clear operating leverage, not the persistent losses bears feared.

The bigger support for the cautious view sits in milestones missed around guidance and pricing. Management cut the 2026 TTR revenue range by about US$200m at the midpoint and tied this to pent up second line demand fading. That speaks directly to early saturation risk rather than pure execution upside. Product gross margin slipped to 75% as royalties rose and net price declined modestly. Combined with non GAAP R&D of US$377m and SG&A of US$297m, the print shows profitable scale, but not cost or pricing relief.

With Alnylam Pharmaceuticals now profitable but trading at a premium P/E and maintaining heavy ongoing R&D, are current cash flows and the balance sheet strong enough to support this growth push without strain? Verify the funding runway and debt capacity in the financial health analysis of Alnylam Pharmaceuticals stock.

Stay Ahead With Simply Wall St

If Alnylam Pharmaceuticals catching over US$1.2b in quarterly product sales while the share price barely moved has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch for a more attractive entry point. After you decide to take a position, keep your focus on what really matters by managing your holdings through the Portfolio Command Center that highlights only the most important updates. For a longer term view, tap into the crowd insight and different angles on Alnylam Pharmaceuticals and other stocks inside the Community. This combination helps you surface hidden catalysts and risks early so you can stay ahead of the market.

Curious To Seek Alternatives Beyond Alnylam

Fresh stock stories can catch breakout momentum fast, then slip away once the crowd piles in. Scan under the radar ideas while it matters and get in early.

• Track cash rich companies quietly building momentum and compare their fundamentals using the curated list of solid balance sheet and fundamentals stocks (46 results) before the rest of the market catches on.
• Spot potential income workhorses with sturdy payouts by reviewing the hand picked 9 dividend fortresses while yields and prices still look compelling.
• Identify early stage growth candidates with strong financials by scanning the focused 21 elite penny stocks with strong financials before any rise in interest leads to higher valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com